Xenetic Biosciences, Inc. (XBIO)
NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous Close | 3.7700 |
| Open | 3.9901 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 3.9901 - 4.1299 |
| 52 Week Range | 2.5500 - 5.9700 |
| Volume | |
| Avg. Volume | 5,692 |
| Market Cap | 6.301M |
| Beta (5Y Monthly) | 2.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7100 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Xenetic Biosciences ( NASDAQ:XBIO ) Full Year 2023 Results Key Financial Results Revenue: US$2.54m (up 49% from FY...
ACCESSWIREXenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, ...
ACCESSWIREXenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a ...
© 2024 Yahoo. All rights reserved.